The US Food and Drug Administration (FDA) has cleared Echometrix's musculoskeletal visualization technology.
The proprietary technology software, which is designed for compatibility with ultrasound equipment, generates color maps to help trained clinicians visualize structural characteristics of tendons, ligaments and muscles.
Echometrix CEO Sam Adams said the FDA’s clearance of EchoSoft will help patients and clinicians better understand musculoskeletal conditions at both initial diagnosis and during rehabilitation.
"By enabling wider use of ultrasound for musculoskeletal evaluation with our EchoSoft product, we can lower medical imaging costs by helping to reduce dependence on MRI," Adams added.
"By achieving this milestone, we have created significant value, not only for clinicians and patients, but for our shareholders, as well."